Acetate salt of buprenorphine and methods for preparing buprenorphine
The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
1. A crystalline form of the acetate salt of buprenorphine comprising a hydrate, wherein the hydrate is a tetrahydrate.
2. The crystalline form of claim 1 , characterized by an X-ray powder diffraction pattern obtained by exposure to CuKα radiation comprising peaks at 2θ angles substantially equivalent to 16.21 and 18.70, and having at least one additional peak at a 2θ angle substantially equivalent to 8.77, 10.31, or 18.47.
3. The crystalline form of claim 1 , characterized by an X-ray powder diffraction pattern obtained by exposure to CuKα radiation comprising peaks at 2θ angles substantially equivalent to 8.77, 10.31, 16.21, and 18.70, and having at least one additional peak at a 2θ angle substantially equivalent to 6.38, 11.93, or 19.40.
4. The crystalline form of claim 1 , characterized by an X-ray powder diffraction pattern obtained by exposure to CuKα radiation comprising peaks at 2θ angles substantially equivalent to 8.77, 10.31, 16.21, 18.47, and 18.70, and having at least one additional peak at a 2θ angle substantially equivalent to 6.38, 11.93, or 19.40.
5. The crystalline form of claim 1 , characterized by an X-ray powder diffraction pattern obtained by exposure to CuKα radiation comprising peaks at diffraction angles substantially equivalent to at least those in the following table:
Position [°2Theta]
6.38
8.77
10.31
11.93
16.21
18.70
19.40.
6. The crystalline form of claim 1 , characterized by an X-ray powder diffraction pattern obtained by exposure to CuKα radiation comprising peaks at diffraction angles substantially equivalent to at least those in the following table
Position [°2Theta]
6.38
8.77
10.31
11.93
16.21
18.47
18.70
19.40.
7. The crystalline form of claim 1 , which has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in FIG. 4 when measuring using CuKα radiation.
8. The crystalline form of claim 1 , wherein the crystalline form exhibits a first transition region with at least one peak position at from about 50° C. to about 140° C. as measured by a heat flow differential scanning calorimeter at a heating rate of about 10° C. per minute.
9. The crystalline form of claim 8 , wherein the crystalline form exhibits a second transition region having a peak position at from about 217° C. to about 225° C. as measured by a heat flow differential scanning calorimeter at a heating rate of about 10° C. per minute.
10. The crystalline form of claim 9 , which exhibits an integral ratio of from about 7 to about 8 for the first transition region at from about 50° C. to about 140° C. relative to the second transition region at from about 217° C. to about 225° C., wherein the integrals are determined over the temperature ranges of from about 35° C. to about 180° C. and from about 203° C. to about 233° C., respectively.
11. The crystalline form of claim 10 , wherein the crystalline form exhibits an integral ratio of from about 7.1 to about 7.8.
12. The crystalline form of claim 3 , characterized in that it is a monoclinic crystal.
13. The crystalline form of claim 5 , characterized in that it is a monoclinic crystal.
14. The crystalline form of claim 9 , characterized in that it is a monoclinic crystal.
15. The crystalline form of claim 12 , wherein the unit cell parameters are a=10.5±0.5 Å, b=10.9±0.5 Å, and c=14.4±0.5 Å.
16. The crystalline form of claim 15 , wherein the unit cell parameters are a=10.52±0.05 Å, b=10.92±0.05 Å, and c=14.44±0.05 Å.
17. The crystalline form of claim 12 , wherein the space group is P2 1 .
18. The crystalline form of claim 13 , wherein the space group is P2 1 .
19. The crystalline form of claim 14 , wherein the space group is P2 1 .
20. A pharmaceutical composition comprising the crystalline form of claim 1 , and a pharmaceutically acceptable carrier.
21. A method for treating pain comprising administering to an animal in need thereof an effective amount of the crystalline form of claim 1 .
22. A method for treating pain comprising administering to an animal in need thereof an effective amount of the pharmaceutical composition of claim 20 .